Womed Leaf Resorbable Adhesion Barrier
Womed Sas · Decision date Sep 9, 2025
What did the FDA approve?
FDA records P240015 as an original PMA application. The recorded decision is approval, dated Sep 9, 2025.
FDA approval order statement
Approval for the Womed Leaf Resorbable Adhesion Barrier is intended to reduce the reoccurrence and severity of post-surgical adhesion formation inside the uterus. It is indicated for adult women undergoing hysteroscopic surgery for symptomatic moderate to severe intrauterine adhesions.
- Regulatory pathway
- Original PMA
- Clinical specialty
- Obstetrics/Gynecology
- Decision date
- Sep 9, 2025
Regulatory record facts
- Identifier
- P240015
- Regulatory pathway
- Premarket approval application
- Applicant
- Womed Sas
- Product code
- MCN
- Decision code
- APPR
- Decision date
- Sep 9, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Barrier, absorbable, adhesion.
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P240015 received
Application receipt date recorded by FDA.
P240015 · FDA decision
APPR
P240015/S003 · Related supplement
Womed Leaf
Timeline entries are records held by MedtechLedger for P240015. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P240015
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Womed LeafP240015/S003 | Womed Sas | PMA supplement | Oct 25, 2026 | FDA |
Explore the linked device profile
Other records with product code MCN
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
GYNECARE INTERCEED Absorbable Adhesion BarrierP880047/S072 | ETHICON, Inc. | PMA supplement | Nov 5, 2026 | FDA |
Juveena Hydrogel SystemP250051/S001 | Rejoni, Inc. | PMA supplement | Oct 28, 2026 | FDA |
Juveena Hydrogel SystemP250051 | Rejoni, Inc. | PMA approval | Sep 28, 2026 | FDA |
| ETHICON, Inc. | PMA approval | Sep 15, 1989 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Womed Sas
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Batiment Balard Cit, 1919 Rte. De Mende, Montpellier, 34090
Sources and methodology
- Original FDA record: P240015
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records


